The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.43
Ask: 1.45
Change: 0.00 (0.00%)
Spread: 0.02 (1.399%)
Open: 1.42
High: 1.43
Low: 1.42
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

12 Aug 2022 07:00

RNS Number : 7672V
RTW Venture Fund Limited
12 August 2022
 

LEI: 549300Q7EXQQH6KF7Z84

12 August 2022

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 July 2022 (the "NAV") was US$288.1 million, or US$1.36 per ordinary share, an increase of 8.4% on the previous month.

As at 31 July 2022, 29.9 per cent. of the total NAV was invested in privately-held core portfolio companies and 35.4 per cent. of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments. 33.2% was invested in other liquid public positions (which mirror holdings in RTW Investments, LP private funds) in lieu of holding cash for future core investments.

For Further Information:

RTW Investments, LP

+1 (646) 343 9280

Stephanie Sirota, Chief Business Officer

 

Woody Stileman, Managing Director, Strategic Partnerships

 

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 May 2022. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPUQGRUPPGAG
Date   Source Headline
14th Apr 20227:00 amRNSNet Asset Value(s)
4th Apr 20224:23 pmRNSDirector/PDMR Shareholding
4th Apr 20224:22 pmRNSDirector/PDMR Shareholding
31st Mar 20227:00 amRNSAnnual Financial Report
14th Mar 20227:00 amRNSNet Asset Value(s)
7th Mar 20227:00 amRNSNotice of Annual Report
17th Feb 20227:50 amRNSAdditional Investment in Magnolia Medical
16th Feb 202212:45 pmRNSNew Investment in Third Harmonic Bio
14th Feb 20227:00 amRNSNet Asset Value(s)
26th Jan 20222:00 pmRNSNew Investment in Kyverna
24th Jan 20227:00 amRNSQuarterly Update
14th Jan 20227:00 amRNSNet Asset Value(s)
12th Jan 20228:05 amEQSEdison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment
10th Jan 20227:00 amRNSPortfolio Company Update: CinCor Pharma IPO
14th Dec 20217:00 amRNSNet Asset Value(s)
12th Nov 20217:00 amRNSNet Asset Value(s)
26th Oct 20217:00 amRNSQuarterly Update
22nd Oct 20217:00 amRNSPortfolio Company Update: Ventyx IPO
14th Oct 20217:00 amRNSNet Asset Value(s)
13th Oct 20217:00 amRNSNew Investment in CinCor Pharma
11th Oct 20217:00 amRNSPortfolio Company Update: Pyxis IPO
1st Oct 20217:00 amRNSTotal Voting Rights
21st Sep 20217:00 amRNSDirector/PDMR Shareholding
20th Sep 20217:00 amRNSIssue of Equity
16th Sep 20215:48 pmRNSAnnouncement of Share Issuance
16th Sep 20217:00 amRNSHalf-year Report
15th Sep 20217:00 amRNSNet Asset Value(s)
9th Sep 202112:00 pmRNSNew Investment in Lycia
9th Sep 20217:00 amRNSNew Investment in InBrace
1st Sep 20217:00 amRNSTotal Voting Rights
19th Aug 20217:05 amRNSDirector/PDMR Shareholding
19th Aug 20217:05 amRNSDirector/PDMR Shareholding
19th Aug 20217:00 amRNSNotice of Interim Report
17th Aug 20217:00 amRNSIssue of Equity
13th Aug 20214:05 pmRNSAnnouncement of Share Issuance
13th Aug 20217:00 amRNSNet Asset Value(s)
6th Aug 20217:00 amRNSCompletion of Transfer
5th Aug 20211:00 pmRNSTransfer to the Premium Segment of the LSE
2nd Aug 20217:01 amRNSPortfolio Company Update: Tenaya Therapeutics IPO
2nd Aug 20217:00 amRNSQuarterly Update
30th Jul 20213:50 pmRNSResult of Meeting
27th Jul 20217:05 amRNSNew Investment in Artios
15th Jul 20217:00 amRNSNet Asset Value(s)
14th Jul 20217:05 amRNSPortfolio Company Update
14th Jul 20217:00 amRNSPublication of Circular
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:00 amRNSPortfolio Company Update: GH Research IPO
25th Jun 20217:00 amRNSPortfolio Company Update: Monte Rosa IPO
22nd Jun 20214:49 pmRNSResult of AGM
18th Jun 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.